Literature DB >> 10413205

Immunological abnormalities in primary APS evolving into SLE: 6 years follow-up in women with repeated pregnancy loss.

J Carbone1, M Orera, M Rodríguez-Mahou, C Rodríguez-Pérez, S Sánchez-Ramón, E Seoane, J J Rodríguez, J M Zabay, E Fernández-Cruz.   

Abstract

We have performed a prospective study to determine the prevalence of immunological abnormalities and the evolution from primary antiphospholipid syndrome (APS) into systemic lupus erythematosus (SLE) in women who had had unexplained repeated pregnancy loss (PL) and APS. Of 105 women with abortions or fetal deaths, 33(31%) fulfilled criteria for APS. Among these patients with primary APS, 24% had antinuclear antibodies (ANA), 91% had elevated circulating immune complexes (CIC), 70% had low total haemolytic complement (CH100), 52% had low levels of complement 4 (C4) and 30% had low levels of complement 3 (C3), in a significantly higher prevalence than women whose pregnancies were successful (control group). Through out a 6 y follow-up, 3 (9%) of the patients with APS who had autoimmune related abnormalities when entered into the study developed features of lupus like disease (LLD) or fullblown SLE. Our findings suggest that women with unexplained repeated PL with APS who presented with positive ANA, high levels of CIC, low levels of CH100, C3 and C4, may define a subset of patients exhibiting immunological alterations similar to those of SLE. These parameters may help in the assessment of prognosis in APS patients with PL. Those patients should be carefully surveyed with regard to the development of connective tissue diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10413205     DOI: 10.1191/096120399678847777

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  9 in total

Review 1.  Defects in the disposal of dying cells lead to autoimmunity.

Authors:  Udo S Gaipl; Sandra Franz; Reinhard E Voll; Ahmed Sheriff; Joachim R Kalden; Martin Herrmann
Journal:  Curr Rheumatol Rep       Date:  2004-12       Impact factor: 4.592

Review 2.  Is there a microangiopathic antiphospholipid syndrome?

Authors:  Ronald A Asherson; Sylvia S Pierangeli; Ricard Cervera
Journal:  Ann Rheum Dis       Date:  2007-04       Impact factor: 19.103

3.  C6 knock-out mice are protected from thrombophilia mediated by antiphospholipid antibodies.

Authors:  Al Carrera-Marín; Z Romay-Penabad; E Papalardo; E Reyes-Maldonado; E García-Latorre; G Vargas; T Shilagard; S Pierangeli
Journal:  Lupus       Date:  2012-08-29       Impact factor: 2.911

4.  Primary Antiphospholipid Syndrome Associated with Autoantibodies Against Golgi Bodies: A Case Report of a 32-Year-Old Female.

Authors:  Neha Rani Verma; Suprava Patel; Rachita Nanda; Eli Mohapatra
Journal:  Indian J Clin Biochem       Date:  2018-10-20

Review 5.  Complement activation and pregnancy failure.

Authors:  Angela Tincani; Ilaria Cavazzana; Tamara Ziglioli; Andrea Lojacono; Valentina De Angelis; Pierluigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2010-12       Impact factor: 8.667

6.  Distinct antibody profile: a clue to primary antiphospholipid syndrome evolving into systemic lupus erythematosus?

Authors:  Paula Vieira Freire; Elisa Watanabe; Nelita Rocha dos Santos; Cleonice Bueno; Eloísa Bonfá; Jozélio Freire de Carvalho
Journal:  Clin Rheumatol       Date:  2014-01-14       Impact factor: 2.980

Review 7.  Predictors of pregnancy outcome in antiphospholipid syndrome: a review.

Authors:  Sara De Carolis; Angela Botta; Stefania Santucci; Serafina Garofalo; Carmelinda Martino; Alessandra Perrelli; Silvia Salvi; Sergio Ferrazzani; Leonardo Caforio; Giovanni Scambia
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

Review 8.  Mechanisms of aPL-mediated thrombosis: effects of aPL on endothelium and platelets.

Authors:  Mariano E Vega-Ostertag; Silvia S Pierangeli
Journal:  Curr Rheumatol Rep       Date:  2007-06       Impact factor: 4.686

9.  CD8+DR+ T-Cells and C3 Complement Serum Concentration as Potential Biomarkers in Thrombotic Antiphospholipid Syndrome.

Authors:  Elizabeth Sarmiento; Jonathan Dale; Mauricio Arraya; Antonio Gallego; Nallibe Lanio; Joaquin Navarro; Javier Carbone
Journal:  Autoimmune Dis       Date:  2014-05-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.